Pathology & Oncology Research

, Volume 21, Issue 4, pp 1183–1189 | Cite as

Determination of Tumor Heterogeneity in Colorectal Cancers Using Heterogeneity Tissue Microarrays

  • Phillip R. Stahl
  • Jessica Schnellert
  • Christina Koop
  • Ronald Simon
  • Andreas Marx
  • Jakob R. Izbicki
  • Guido Sauter
  • Alexander Quaas


Cancer is often heterogeneous both on a morphological and on a genetic level. Though resected tumors are often large, molecular tumor analysis is usually restricted to one tissue block. In this project we introduce a new tool for a high-throughput heterogeneity analysis of colorectal cancer. A heterogeneity tissue microarray (TMA) was manufactured from tissues of 340 patients with colorectal cancer. For this purpose 8 different tissue spots were taken from as many different cancer blocks per patient as possible (at least 4 different blocks). Additional tissue samples from 1 to 4 corresponding lymph node metastases were added from 134 patients. The system was then validated by analysing one parameter each known for minimal (p53) or substantial (HER2) heterogeneity in colorectal cancer. P53 alterations as detected by immunohistochemistry were seen in 174 (51.3 %) of 339 analyzable primary tumors of which 23 (13.2 % of positive cases) showed a heterogeneous distribution pattern. HER2 overexpression was seen in 18 (5.4 %) of 336 evaluable tumors. HER2 amplification occurred in 6 (33.3 %) of the 18 cases with HER2 overexpression. Genomic heterogeneity was more prevalent for HER2 alterations than for p53 alterations. For immunohistochemical expression analysis, 16 of 18 positive cases were heterogeneous (88.9 %) and for amplification 3 of 6 cases (50 %) were heterogeneous. Large section validation revealed, however a considerable fraction of heterogeneous cases were due to technical artifacts. In summary, our data suggest, that heterogeneity TMAs are a powerful tool to rapidly screen for molecular heterogeneity in colorectal cancer.


Tissue microarrays Colorectal cancer Heterogeneity p53 HER2 


  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMedGoogle Scholar
  2. 2.
    Lombardi L, Morelli F, Cinieri S et al (2010) Adjuvant colon cancer chemotherapy: where we are and where we’ll go. Cancer Treat Rev 36:S34–S41CrossRefPubMedGoogle Scholar
  3. 3.
    Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417CrossRefPubMedGoogle Scholar
  4. 4.
    Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767CrossRefPubMedGoogle Scholar
  5. 5.
    Vousden KH, Prives C (2009) Blinded by the light: the growing complexity of p53. Cell 137:413–431CrossRefPubMedGoogle Scholar
  6. 6.
    Levine AJ, Oren M (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9:749–758PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Russo A, Bazan V, Iacopetta B et al (2005) The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23:7518–7528CrossRefPubMedGoogle Scholar
  8. 8.
    Munro AJ, Lain S, Lane DP (2005) P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 92:434–444PubMedCentralPubMedGoogle Scholar
  9. 9.
    Jourdan F, Sebbagh N, Comperat E et al (2003) Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 443:115–121CrossRefPubMedGoogle Scholar
  10. 10.
    Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P (1991) p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 63:317–319PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Rubin I, Yarden Y (2001) The basic biology of HER2. Ann Oncol 12:S3–S8CrossRefPubMedGoogle Scholar
  12. 12.
    Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy and a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792CrossRefPubMedGoogle Scholar
  13. 13.
    Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697, Epub 2010 Aug 19. Erratum in: Lancet. Oct 16;376(9749):1302CrossRefPubMedGoogle Scholar
  14. 14.
    Tapia C, Glatz K, Novotny H et al (2007) Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol 20:192–198CrossRefPubMedGoogle Scholar
  15. 15.
    Hu Y, Bandla S, Godfrey TE et al (2011) HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol 24:899–907PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK (2010) Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 16:2266–2274PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Burandt E, Schreiber M, Stein A et al (2014) Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice. Genes Chromosomes Cancer 53:228–239CrossRefPubMedGoogle Scholar
  18. 18.
    Ramanathan RK, Hwang JJ, Zamboni WC et al (2004) Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Investig 22:858–865CrossRefGoogle Scholar
  19. 19.
    Saunders NA, Simpson F, Thompson EW et al (2012) Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med 4:675–684PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Minner S, Gärtner R, Freudenthaler F et al (2013) Marked heterogeneity of ERG expression in large primary prostate cancers. Mod Pathol 26(1):106–116CrossRefPubMedGoogle Scholar
  21. 21.
    Simon R, Mirlacher M, Sauter G (2005) Tissue microarrays. Methods Mol Med 114:257–268PubMedGoogle Scholar
  22. 22.
    Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J (2004) Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 17:790–797CrossRefPubMedGoogle Scholar
  23. 23.
    Graham AD, Faratian D, Rae F, Thomas JS (2008) Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology 52:847–855CrossRefPubMedGoogle Scholar
  24. 24.
    Bhargava R, Lal P, Chen B (2004) Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma. Diagn Mol Pathol 13:213–216CrossRefPubMedGoogle Scholar
  25. 25.
    Sauter G, Lee J, Barlett JM, Slamon DJ, Press MF (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323–1333CrossRefPubMedGoogle Scholar
  26. 26.
    Fernebro E, Dictor M, Bendahl PO, Fernö M, Nilbert M (2002) Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med 126:702–705PubMedGoogle Scholar
  27. 27.
    Kountourakis P, Pavlakis K, Psyrri A et al (2006) Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer J 12:229–236CrossRefPubMedGoogle Scholar
  28. 28.
    Nathanson DR, Culliford AT, Shia J et al (2003) HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 105:796–802CrossRefPubMedGoogle Scholar
  29. 29.
    Marx AH, Burandt EC, Choschzick M et al (2010) Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol 41:1577–1585CrossRefPubMedGoogle Scholar
  30. 30.
    McKay JA, Loane JF, Ross VG et al (2002) c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer 86:568–573PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Maurer CA, Friess H, Kretschmann B et al (1998) Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 29:771–777CrossRefPubMedGoogle Scholar
  32. 32.
    Seidal T, Balaton AJ, Battifora H (2001) Interpretation and quantification of immunostains. Am J Surg Pathol 25:1204–1207CrossRefPubMedGoogle Scholar
  33. 33.
    Prat A, Parera M, Reyes V et al (2008) Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck 30:680–683CrossRefPubMedGoogle Scholar
  34. 34.
    Cappuzzo F, Bemis L, Varella-Garcia M (2006) HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 354:2619–2621CrossRefPubMedGoogle Scholar
  35. 35.
    Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S (2008) Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet 102:128–131CrossRefPubMedGoogle Scholar
  36. 36.
    Karam A, Berek JS, Stenson A, Rao J, Dorigo O (2008) HER-2/neu targeting for recurrent vulvar Paget’s disease A case report and literature review. Gynecol Oncol 111:568–571CrossRefPubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2015

Authors and Affiliations

  • Phillip R. Stahl
    • 1
  • Jessica Schnellert
    • 1
  • Christina Koop
    • 1
  • Ronald Simon
    • 1
  • Andreas Marx
    • 1
  • Jakob R. Izbicki
    • 2
  • Guido Sauter
    • 1
  • Alexander Quaas
    • 1
  1. 1.Institute of PathologyUniversity Medical Center Hamburg-EppendorfHamburgGermany
  2. 2.General, Visceral and Thoracic Surgery DepartmentUniversity Medical Center Hamburg-EppendorfHamburgGermany

Personalised recommendations